Altogether these findings indicate that higher circulating FGF-21 levels observed in patients with NAFLD than controls may be primarily attributed to more severe disease; however, the interpretation of this result should be approached with caution, because of the relatively small number of studies with histological confirmation or with the inclusion of patients with NASH-related cirrhosis. Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.